BioNTech Stock Plummets: Q4 Loss, Founders Depart, Outlook Cut

The biotechnology company reported a net loss of 305.0 million euros for the fourth quarter, a significant downturn from the 259.5 million euros net income in the same period last year. Further dampening investor sentiment, BioNTech provided a weak financial outlook for fiscal year 2026, forecasting total revenues between 2.0 billion euros and 2.3 billion euros, a substantial reduction from the 2.87 billion euros projected for fiscal 2025.

Adding to the market's apprehension, co-founders Ugur Sahin and Özlem Türeci revealed plans to exit by the end of 2026 to establish a new, independent biotechnology venture. This combination of financial underperformance, reduced guidance, and a critical leadership transition has triggered a sharp sell-off, with shares trading around $80.24, reflecting significant investor concern over the company's future trajectory and stability.